PF-04217903
PF-04217903 is a triazolopyrazine inhibitor of c-MET that displays anticancer chemotherapeutic and anti-metastatic activities. PF-04217903 inhibits cell proliferation, invasion, and migration as well as tumor growth in various cancer models. In animal models of pancreatic neuroendocrine tumors, this compound prevents lymph node metastasis.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18953027
| Cas No. |
1159490-85-3 |
|---|---|
| Purity |
≥98% |
| Formula |
C19H16N8O |
| Formula Wt. |
372.38 |
| IUPAC Name |
2-{4-[1-(6-Quinolinylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl]-1H-pyrazol-1-yl}ethanol |
| Synonym |
PF04217903 |
| Appearance |
White to off white powder |
Sennino B, Ishiguro-Oonuma T, Schriver BJ, et al. Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice. Cancer Res. 2013 Jun 15;73(12):3692-703. PMID: 23576559.
Zou HY, Li Q, Lee JH, et al. Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor. Mol Cancer Ther. 2012 Apr;11(4):1036-47. PMID: 22389468.
Timofeevski SL, McTigue MA, Ryan K, et al. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. Biochemistry. 2009 Jun 16;48(23):5339-49. PMID: 19459657.
